Ladenburg analyst Ahu Demir downgraded Ayala Pharmaceuticals to Neutral from Buy and removed the firm’s prior price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADXS:
- Ayala Pharmaceuticals receives Orphan Drug Designation for AL102
- Ayala Pharmaceuticals treatment of desmoid tumors granted orphan designation
- Ayala Pharmaceuticals presents updated AL102 results at ESMO congress
- Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
- Ayala Pharmaceuticals closes merger with Biosight